Global /Japan /Healthcare /Drug Manufacturers - General /4592

SanBio Company Ltd.

4592

• TSE: 4592 • Delayed

1,875JPY -5.2%

11.72 USD

As of 5 June 2026, SanBio Company Ltd. has a market cap of $964.03M USD, ranking #10916 globally and #784 in Japan. It ranks #983 in the Healthcare sector, and #363 in the Drug Manufacturers - General industry.

Global Rank

10916

Country Rank

784

Sector Rank

983

Industry Rank

363

Key Stats

Market Cap

$964.03MUSD

154.27B JPY

Enterprise Value

$877.52MUSD

140.43B JPY

EBITDA (TTM)

-$23.66MUSD

-3.79B JPY

Net Income (TTM)

-$24.01MUSD

-3.84B JPY

PB Ratio

11.3

Company Profile

Country (HQ)

Japan

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Keita Mori open_in_new

Employees

Founded

2001

Website

sanbio.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-5.2%	-9.3%	5.2%	4.2%	-29%	17%	-4.6%	214%	27%

Upcoming Earnings

Earnings Date

Fri, Jun 12

News

Markets

Exchange	Ticker	Price	Quotes
Tokyo Stock Exchange (TSE / TYO) MIC: XTKS PRIMARY	4592 サンバイオ株式会社 ISIN: JP3336750009 Shares Out.: Shares Outstanding: 78.058M¹ Shares Float: 58.827M² TV: TradingView: TSE: 4592 SA: Stock Analysis: TYO: 4592 YF: Yahoo Finance: 4592.T GF: Google Finance: TYO: 4592 BA: Barron's: 4592 MS: Morningstar: XTKS: 4592	1,875 JPY	TV: TradingView: TSE: 4592 SA: Stock Analysis: TYO: 4592 YF: Yahoo Finance: 4592.T GF: Google Finance: TYO: 4592 BA: Barron's: 4592 MS: Morningstar: XTKS: 4592
OTC Markets (OTCMKTS / OTC) MIC: OTCM	SNBIF サンバイオ株式会社 ISIN: JP3336750009 Shares Out.: Shares Outstanding: 72.017M¹ Shares Float: 51.978M² TV: TradingView: OTC: SNBIF SA: Stock Analysis: OTC: SNBIF YF: Yahoo Finance: SNBIF GF: Google Finance: OTCMKTS: SNBIF BA: Barron's: SNBIF MS: Morningstar: PINX: SNBIF	16.45 USD	TV: TradingView: OTC: SNBIF SA: Stock Analysis: OTC: SNBIF YF: Yahoo Finance: SNBIF GF: Google Finance: OTCMKTS: SNBIF BA: Barron's: SNBIF MS: Morningstar: PINX: SNBIF

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About SanBio Company Ltd.

SanBio Company Limited engages in the development, production, and sale of regenerative cell medicines for the central nervous system. It develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. The company’s research pipeline products also comprise SB623 for chronic cerebral infarction and chronic traumatic cerebral infarction injury, chronic cerebral hemorrhage, age-related macular degeneration, retinitis pigmentosa, spinal cord injury, Parkinson's disease, Alzheimer's disease, etc.; SB618 for peripheral neuropathy; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.

Similar Companies

Industry: Drug Manufacturers - General (Japan)

Name	Market Cap (USD) diff.	PE	Country
Chugai Pharmaceutical Co., Ltd. TSE: 4519	$81.66B 13.07T JPY 8K%	28.9	Japan
Takeda Pharmaceutical Company Ltd. TSE: 4502	$52.21B 8.36T JPY 5K%	75.1	Japan
Otsuka Holdings Co., Ltd. TSE: 4578	$36.84B 5.9T JPY 4K%	15.7	Japan
Daiichi Sankyo Company, Ltd. TSE: 4568	$30.37B 4.86T JPY 3K%	16.2	Japan
Astellas Pharma Inc. TSE: 4503	$25.82B 4.13T JPY 3K%	14.2	Japan
Shionogi & Co., Ltd. TSE: 4507	$16.91B 2.71T JPY 2K%	13.9	Japan

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 79K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 57K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 37K%	97.4	United States
Roche Holding AG SIX: RO	$323.4B 256.25B CHF 33K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$289.25B 215.59B GBP 30K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$276.26B 218.9B CHF 29K%	20.5	Switzerland

chevron_leftBack